Author: Rachael Hansford

World Brain Day: Clean Air for Brain Health

Posted on July 20, 2018 by - Neurology News

22 July: World Brain Day 2018 – Clean Air for Brain Health

Global air pollution is not a problem that only affects lung health. Recent data show that airborne pollutants account for 30 percent of acute stroke cases worldwide. Cleaning up the air we breathe would help to prevent various serious and common neurological disorders, as the World Federation of Neurology aims to emphasise on World Brain Day 2018, which is devoted to highlighting the negative impact of air pollution on brain health.

Every year on 22 July, the World Federation of Neurology (WFN) stages World Brain Day. Around 120 organisations around the world participate in this awareness-raising initiative. The focus in 2018 is a topic that is growing in importance as a result of a number of recent scientific studies: the negative effects of high air pollution levels on the brain. “Clean Air for Brain Health” is this year’s theme.

The impact on health of environmental pollution, and air pollution in particular, is increasing all the time. Recent estimates put the annual number of deaths attributable to polluted air at 9 million worldwide.

“The Global Burden of Disease study, carried out by an international team using data from 188 countries, found that up to 30 percent of the global stroke burden can be traced back to pollutants in the air,” explained World Brain Day Chair Prof Mohammad Wasay from Karachi. “This was the reason behind our decision to select an aspect of environmental pollution as the theme for World Brain Day 2018.”

A complex global problem


The connection between harmful gases and particles in the air and brain health is a worldwide problem, and also a complex one. According to Prof Jacques Reis, head of the World Federation of Neurology’s Environmental Neurology Applied Research Group:

Air pollution refers to diffuse, often invisible contamination by damaging bioaerosols containing pollen, spores, particles and toxic substances. The pollutants can stem from natural sources or may be due to human activity.”

Additionally, the phenomenon can vary sharply – both quantitatively and qualitatively – depending on the situations in which people live and work. It includes:

  • Indoor air pollution, e.g. from heating systems, cooking on open wood fires, kerosene and tobacco
  • Outdoor pollution, e.g. industrial and vehicle exhaust fumes, waste incineration and dust
  • A distinction is made between primary and secondary air pollutants: the former are gases and particles that themselves have harmful effects, while the latter are the result of chemical reactions between natural and/or man-made substances (such as ozone)

“The problem is different in major cities compared with rural areas. Some air pollutants have a local or regional impact, but the effects of others can be international,” says Prof Reis.

In May this year, the World Health Organisation (WHO) found that nine-tenths of the world’s population breathe polluted air. And three billion people use harmful fuels in their homes for cooking and/or heating.

Understanding of toxic effects constantly improving

In recent years, scientists have uncovered significant evidence of the way in which air pollution affects the brain, and how this is damaging neurological health all over the world. As Prof Reis explains: “Pollutants enter the body through the respiratory and alimentary tracts. They cause subthreshold inflammatory responses, and reach the brain either via the blood stream or the upper respiratory tract. The resulting damage to intestinal microbiota can also have an impact on the brain.”

The list of potential effects is long: atherosclerosis, oxidative stress, inflammatory responses throughout the body, blood vessel damage, increased blood pressure, impairment of the blood-brain barrier’s protective mechanisms, and heart problems could be connected to air pollution. Possible damage to brain cells such as microglia cells and astrocytes has also been identified. At the cellular level, air pollutants interfere with mitochondria – often referred to as cells’ “powerhouses” – and genetic material like DNA. Pollutants bring about epigenetic changes and shorten telomeres, the protective caps on the ends of chromosomes. The latter is seen as a sign of cell ageing.

Little wonder, then, that air pollution is suspected of playing a part in a growing number of syndromes and neurological diseases. Initial findings suggest it could play a role in autism, attention deficit disorders in children, dementia and the development of Parkinson’s disease, although reliable data are not yet available.

Caused by humans – but modifiable

Decisive changes in behaviour could significantly reduce the risks posed by environmental factors that cause brain health to deteriorate. “Preventing neurological disorders is not just a concern for individuals; action needs to be taken at the societal level as well. This is particularly true of man-made environmental impacts, which mankind in turn can ultimately influence. These are important risk factors for diseases affecting the blood vessels in the brain, as well as neurodegenerative conditions,” said Prof Wolfgang Grisold, the WFN’s Secretary General.

“This worldwide public health problem requires effective environmental and health-policy strategies aimed at reducing air pollution. It is not just a matter of lung health, but the health of the very organ that makes us humans: our brains,” Prof Grisold emphasised.

Wake-up call for the international community

Speaking about this year’s World Brain Day, WFN President Prof William Carroll believed that there is only one possible interpretation of the available scientific data on the effects of air pollution on brain health: “Each and every one of us, every country in the world and the international community must see this as a wake-up call. Policymakers need to do more to tackle neurological disorders and diseases. This means making brain health one of the highest-level healthcare priorities and providing additional funds to address the issue.”

The annual World Brain Day takes place on 22 July and is devoted to a different topic each year. The choice of date was no coincidence: the WFN was founded on 22 July 1957.

INSIGHTEC’s Focused Ultrasound Earns Positive NICE Guidance for Treatment of Essential Tremor

Posted on July 2, 2018 by - Industry News

Unilateral MRI-guided Focused Ultrasound Thalamotomy for Treatment-resistant Essential Tremor Recognised by National Institute for Health and Care Excellence

INSIGHTEC®, a global medical technology innovator of incisionless surgery, has announced that The National Institute for Health and Care Excellence (NICE) issued a positive NICE guidance for unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (ET). ET affects more than one million people in the UK and impacts their ability to perform everyday tasks due to uncontrollable shaking of their hands.

The Imperial College Healthcare NHS Trust is the first and only site in the UK with the Exablate Neuro™ technology to treat essential tremor. To date 16 patients with ET have been treated at St. Mary’s by an expert, multidisciplinary team including Professor Wladyslaw Gedroyc, Consultant Radiologist, Dr. Peter Bain, Consultant Neurologist and Professor Dipankar Nandi, Consultant Neurosurgeon.

Essential tremor patients treated at St Mary’s have experienced very substantial improvement in the severity of their tremor as well as their quality of life. In addition, the safety profile is favourable with minor, often temporary side effects experienced by this group.

Professor Dipankar Nandi, Consultant Neurosurgeon and Head of Department, St Mary’s Hospital, Imperial College Healthcare NHS Trust. 

During the treatment, ultrasound waves pass safely through the skull to ablate a tiny spot in the brain considered to be responsible for the tremor. The result is often an immediate improvement of the tremor in the treated hand. Due to the incisionless nature of focused ultrasound, there is no risk of infection and patients recover quickly.

The positive NICE guidance adds to the growing body of positive health technology determinations for incisionless brain surgery using INSIGHTEC’s Exablate Neuro. This is a critical step toward increased patient access to our technology around the globe.

Maurice R. Ferré, MD, Chief Executive Officer and Chairman of the Board of INSIGHTEC

For more information on the NICE guidance, please visit NICE.org.uk.

About INSIGHTEC

INSIGHTEC is a global medical technology innovator transforming patient lives through incisionless brain surgery using MR-guided focused ultrasound. The company’s award-winning Exablate Neuro™ is used by neurosurgeons to perform the Neuravive™ treatment to deliver immediate and durable tremor relief for essential tremor patients.  Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Tokyo and Shanghai.

For more information, please visit: http://www.insightec.com/

NICE recommends OCREVUS®▼ (ocrelizumab) for people with relapsing-remitting multiple sclerosis

Posted on June 22, 2018 by - Industry News

Significant milestone for people with multiple sclerosis as people with relapsing-remitting form gain access to new first-in-class treatment with twice-yearly dosing

22 June 2018, Welwyn Garden City – The National Institute for Health and Care Excellence (NICE) today published a positive final appraisal determination (FAD) for OCREVUS® (ocrelizumab) to treat people living with relapsing-remitting multiple sclerosis (RRMS).[i]

NICE has recommended the use of ocrelizumab for treating RRMS in adults with active disease, defined by clinical or imaging features, when alemtuzumab is contraindicated or otherwise unsuitable.1 Ocrelizumab is a first-in-class treatment with twice-yearly dosing and has less burdensome monitoring requirements than currently available disease-modifying treatments.

The NICE announcement is a significant milestone for people with RRMS who gain access to a new treatment option. Ocrelizumab has been shown to reduce the number of relapses per year by nearly half and slow the risk of progression of the disease compared with current treatment, subcutaneous interferon beta-1a.[ii]

The majority of people with multiple sclerosis (MS) have a relapsing-remitting form at diagnosis with 100 people in the UK diagnosed with MS every week.[iii],[iv] MS affects approximately 100,000 people across the UK with 85 percent of those suffering from RRMS.4,[v]

There is significant unmet need in the treatment of MS, particularly for those with PPMS who currently have no disease-modifying treatment options. We welcome this positive NICE review for RRMS, and hope that it brings us closer to the treatment being made available to people with early PPMS too.

Jo Sopala, Director of Development, MS Trust.

NICE review is ongoing for ocrelizumab in early PPMS, for which there is currently no treatment available. Disability accumulates twice as fast in PPMS as in RRMS, meaning that people with PPMS may have to rely on mobility aids or become wheelchair bound, are unable to work, and need carers to look after them sooner.[vi] Ocrelizumab is the first and only licensed treatment for early PPMS which means the process for reimbursement is more complex and will take longer.

As of today, over 50,000 patients have received treatment with ocrelizumab worldwide and we are delighted that NICE has now recognised ocrelizumab as a cost-effective new treatment option for NHS patients with RRMS.  It is important that we continue to work collaboratively with NICE to ensure people with early PPMS are also able to access ocrelizumab through the NHS as soon as possible.

Dr Marius Scholtz, Integrated Franchise Lead,
Neuroscience, Roche Products UK.

References

[i] National Institute for Health and Care Excellence (2018) Final Appraisal Determination: Ocrelizumab for treating relapsing multiple sclerosis. June 2018.

[ii] Ocrevus (Ocrelizumab) Summary of Product Characteristics 2018.

[iv] MS Trust website. Prevalence and Incidence of MS. Available at: https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis. Last accessed June 2018.

[v] Multiple Sclerosis Society. Relapsing Remitting (RRMS). Available at: https://www.mssociety.org.uk/what-is-ms/types-of-ms/relapsing-remitting-rrms. Last accessed June 2018.

[vi] Raghavan K et al. (2015) Progression rates and samples size estimates for PPMS based on the CLIMB study population. Mult Scler J, 21(2) 180- 188.

[vii] Multiple Sclerosis Trust. About MS. Available at: https://www.mstrust.org.uk/about-ms-0. Last accessed: June 2018.

[viii] MS International Federation. What is MS? Available at: https://www.msif.org/about-ms/what-is-ms/. Last accessed June 2018.

[ix] National Multiple Sclerosis Society. Who Gets MS? Available at: https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS. Last accessed June 2018.

[x] Multiple Sclerosis Trust. Nerve damage caused by MS. Available at: https://www.mstrust.org.uk/a-z/nerve-damage-caused-ms. Last accessed June 2018.

[xi] National Multiple Sclerosis Society. MS symptoms. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Last accessed June 2018.

[xii] Ziemssen T, (2005). Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. J Neurol, 252 (5), v38-v45.

[xiii] G. Giovannoni et al. (2016) Brain Health. Time Matters in Multiple Sclerosis. Multiple Sclerosis and Related Disorders (9) S5–S48 Available at: http://www.msard-journal.com/article/S2211-0348(16)30102-X/fulltext#s0010. Last accessed June 2018.

[xiv] National Multiple Sclerosis Society. Types of MS. Available at: https://www.nationalmssociety.org/What-is-MS/Types-of-MS. Last accessed June 2018.

[xv] Multiple Sclerosis Society. Secondary Progressive MS (SPMS). Available at: https://www.mssociety.org.uk/what-is-ms/types-of-ms/secondary-progressive-spms. Last accessed: June 2018.

[xvi] Multiple Sclerosis Trust. Primary progressive MS. Available at: https://www.mstrust.org.uk/a-z/primary-progressive-ms#treatments. Last accessed June 2018.

[xvii] Multiple Sclerosis Society. Primary Progressive (PPMS). Available at: https://www.mssociety.org.uk/what-is-ms/types-of-ms/primary-progressive-ppms. Last accessed June 2018.

[xviii] Multiple Sclerosis Trust. Disease modifying drugs. Available at: https://www.mstrust.org.uk/understanding-ms/ms-symptoms-and-treatments/disease-modifying-drugs-ms-decisions/disease-modifying#work. Last accessed June 2018.

[xix] MS Society. Early treatment. Available at: https://www.mssociety.org.uk/earlytreatment. Last accessed: June 2018.

[xx] Hauser SL, et al. (2017). Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med, 376: 221-234.

[xxi] Montalban X, et al. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med, 376: 209-220.

[xxii] Lehmann-Horn et al. (2013) Targeting B Cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord. 6 (3) 161-173.

[xxiii] Dilillo DJ, et al. (2008). Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol, 180:361–71.

NICE issues guidance on disease modifying therapies for multiple sclerosis

Posted on May 30, 2018 by - Industry News, Neurology News

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending the use of four out of six disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis. Rebif® (interferon β-1a), Avonex® (interferon β-1a), Extavia® (Interferon β-1b) and Copaxone® (glatiramer acetate) have been recommended, within their marketing authorisations, as options for treating relapsing-remitting multiple sclerosis in the NHS provided the companies provide the drugs with the discounts agreed in the patient access schemes. NICE does not recommend Betaferon® (interferon β-1b), concluding that it would not be a good use of NHS resources. NICE has also stated it is not in a position to recommend pegylated interferon β-1a (Plegridy®) and that there will be a separate single technology appraisal for this drug. These recommendations are not intended to affect treatment with a beta interferon or glatiramer acetate that was started in the NHS before this guidance was published.

The National Institute for Health and Care Excellence (NICE) have been appraising the clinical and cost-effectiveness of beta interferons (interferon β-1a (Avonex®, Rebif®), Pegylated interferon β-1a (Plegridy®), and interferon β-1b (Betaferon®/Extavia®) and glatiramer acetate (Copaxone®) in multiple sclerosis, against best supportive care, in the context of a multiple technology appraisal.

The recent FAD follows a preliminary decision in December 2017 to recommend only Extavia® (interferon β-1b) as an option for treating multiple sclerosis

Epistatus®10 mg (in 1 ml) oromucosal solution Midazolam available on NHS prescription is approved for use by both the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG)

Posted on May 2, 2018 by - Industry News

Epistatus is licensed for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy1.  Epistatus is presented “ready-to-use” in a novel, pre-filled, single-dose syringe, in a volume of 1 mL, to provide carers with the confidence that they are administering the correct dose1,2.

Epistatus has been developed specifically for buccal administration. The pre-filled syringe comes in a robust, tamper-resistant pack, which is UV-resistant to maximise shelf life1. It is portable and is carried by your patients at all times2.

The single-dose pack meets the principles of the Medicines Optimisation and NHS RightCare approach to help reduce wastage3and is compliant with the Falsified Medicines Directive that will come into force in February 20194.The NHS price for a single 10mg in 1mL pre-filled syringe is £45.76.

Please visit www.epistatus.co.uk for further information about Epistatus 10mg oromucosal midazolam pre-filled syringe, or to find out more about a budget model to calculate the financial impact of prescribing multipack buccal midazolam versus single-pack Epistatus.

Prescribing information can be found at https://www.epistatus.co.uk/downloads/epistatus_summary_of_product_characteristics.pdf

References:

1) Epistatus 10mg oromucosal solution. Summary of Product Characteristics.

2) Data on file – Excerpts from Epistatus Patent Application.

3) Medicines Optimisation: Helping patients to make the most of medicines. Royal Pharmaceutical Society May 2013.

4) Pharmaceutical waste reduction in the NHS. NHS England, June 2015.

Acquired Brain Injury Alliance Launches Rehabilitation Prescription Campaign

Posted on May 1, 2018 by - Industry News, Neurology News

The Acquired Brain Injury (ABI) Alliance, a collaborative venture between charities, professional groups and industry coalitions working in the field of ABI, launched its Rehabilitation Prescription (RP) Campaign on 1st May.

Speaking at the launch event in London, Professor Michael Barnes, ABI Alliance Chair said: “The Rehabilitation Prescription is a valuable tool that documents the rehabilitation needs of the individual with an ABI. It has no value if the individual with an ABI and their General Practitioner don’t receive a copy. And if the individual and the GP don’t know what rehabilitation is required then no access to services can be planned or implemented”.

The ABI Alliance believes that the RP should be given to every individual, both children, young people and adults with an ABI, on discharge from hospital, with a copy sent to their GP. This will then provide a useful resource for the GP to work with the individual and facilitate access to rehabilitation services in the community, maximising the individual’s health outcomes.

The results of the National Clinical Audit October 2016 ‘Specialist Rehabilitation for Patients with Complex Needs Following Major Injury (NCASRI)’ were discussed at the launch. The NCASRI report showed that although all 22 Major Trauma Centres reported that they routinely complete a RP, in one-third of the centres the RP was either sometimes or always given to the patient, but in the remaining two-thirds it was a clinically-held tool.

A Freedom of Information Request was sent last year to all Clinical Commissioning Groups by the United Kingdom Acquired Brain Injury Forum (UKABIF) asking if they logged RPs. The feedback was poor, only four CCGs were positive and recognition of the RP was inexcusably low.

https://www.abialliance.org/

Renishaw neuromate® stereotactic robot assists SEEG procedures at The Walton Centre, Liverpool

Posted on April 27, 2018 by - Industry News

Neurosurgeons at The Walton Centre, Liverpool, UK, have recently carried out their first two stereoelectroencephalography (SEEG) procedures with the assistance of the Renishaw neuromatestereotactic robot. The Walton Centre is the only NHS Trust in the UK dedicated to neuroscience, and the staff includes many leaders in their areas of expertise. The procedures with a neuromaterobot marks a transition to robot assisted neurosurgery which should see both patients and staff benefitting from reduced procedure times.

SEEG is a procedure used in the treatment of epilepsy. Multiple intracerebral electrodes are inserted into the brain in preplanned trajectories to gather data and map brain activity. By doing this, neurosurgeons aim to identify the region responsible for generating epileptic seizures. Once the epileptogenic region has been identified neurosurgeons can follow up with a tailored resection to remove the problematic tissue.

The epilepsy neurosurgery team at The Walton Centre is led by consultant neurosurgeons Prof. Paul Eldridge and Mr Jibril Osman-Farah, who estimate that the use of the neuromaterobot will reduce procedure times significantly. Following the recent procedures, Prof. Eldridge and Mr Osman-Farah commented: “Accurate targeting by multiple electrodes is essential to understand the location of the epileptic focus, prior to consideration of its excision or ablation. Since there are multiple trajectories to be both planned and executed it is highly suited to a robotic system fulfilling the requirement for a repetitive stereotyped activity. Without the robot it becomes impractical to consider such a series of multiple electrodes in a reasonable length of time for the procedure.”

Renishaw’s neuromate robot can bring benefit to SEEG procedures by assisting with time-efficient positioning of electrodes and dramatically reducing overall procedure time. By accurately aligning the electrodes according to the neurosurgeons pre-planned trajectory, the neuromate robot helps ensure that neurosurgeons safely reach the targeted anatomy.

The Walton Centre, which was able to acquire the robot through charitable support, is now one of a growing number of hospitals worldwide benefitting from improved accuracy and reduced procedure times by working with the neuromate robot. Stuart Campbell, Clinical Sales Development Manager at Renishaw, added: “The time saved during this latest procedure is a great result for the neurosurgeons and for the patient. We look forward to working closely with the team so that patients can continue to benefit from this innovative technology.”

Merck at The AAN

Posted on April 16, 2018 by - Industry News

Merck will be presenting data for MAVENCLAD® (Cladribine Tablets) a treatment for highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features, and Rebif®(interferon beta-1a) at the American Academy of Neurology (AAN) 70th Annual Meeting, April 21-27, 2018, in Los Angeles.

MAVENCLAD® data to be presented includes poster presentations highlighting post-hoc analyses of the CLARITY, CLARITY Extension and ORACLE-MS trials evaluating safety and use in patients with multiple sclerosis (MS), as well as the impact on B- and T-cells. MAVENCLAD® is a short-course oral therapy that is thought to preferentially target lymphocytes which may be integral to the pathological process of relapsing forms of MS (RMS). MAVENCLAD® is currently under clinical investigation and is not approved in the US.

MAVENCLAD® has received marketing authorisation in 35 countries including European Union member countries, Canada, Australia, Argentina, Israel, and the United Arab Emirates. MAVENCLAD® is now available in Germany, UK, Canada, Netherlands, Norway, Denmark, Sweden, Israel, and other markets. The Company plans additional filings for regulatory approval in other countries, including the United States.

Rebif data includes presentations analysing no evidence of disease activity (NEDA), long-term disease activity assessed by the Magnetic Resonance Imaging in MS (MAGNIMS) score, new data on pregnancy outcomes for women being treated with interferon beta, as well as real-world evidence evaluating treatment adherence rates for patients treated with Rebif compared with dimethyl fumarate.

We look forward to presenting data demonstrating advancement in our knowledge of MS, including further scientific information about Mavenclad and Rebif at the 2018 AAN Annual Meeting

said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck.

Meeting attendees can learn more about the Company and participate in the following MS-specific interactive activities by visiting booth #1847:

  • “I’m Balancing MS”: Individuals can understand the balance between healthcare and lifestyle for those facing MS through a mobile art activity. For each participant, we will donate $100 to MS Fitness Challenge, a charity organisation dedicated to educating and training people with MS on the benefits of exercise and nutrition.
  •  “Shine a Light”: Individuals can create their own Light Trail art symbolising what drives their commitment to fighting MS. Participation in the activity will drive a donation to MS Fitness Challenge.

Additionally, Exhibit Hall booth #1957 will host hands-on activities which will allow attendees to gain a better understanding of what it’s like to have MS through virtual reality pods and simulation stations.

The company will also be hosting an Industry Therapeutic Update event entitled Evolving Perspectives and Innovations in Multiple Sclerosis on Wednesday, April 25 from 7:00 p.m.-10:00 pm PDT at the Platinum Ballroom in the JW Marriott Hotel in Los Angeles. Speakers include, Professor Amit Bar-Or, University of Pennsylvania, Philadelphia, PA, Professor Dusan Stefoski, Rush University Medical Center, Chicago, IL and Professor Anthony Traboulsee, University of British Columbia, Vancouver, CA.

AAN Brain Health Fair

The MS InsideOut experience will be exhibited at the AAN Brain Health Fair, a one-day-only event where attendees can learn about the brain and the field of neurology. The event takes place on Friday, April 20 from 10:00 a.m.-4:00 pm PDT at the Los Angeles Convention Center.

Presentations at AAN 2018 include the following accepted abstracts:

Cladribine Tablets Presentations
TitleLead AuthorAbstract/Poster #Presentation Details
Effects of Cladribine Tablets on CD4+ T-cell Subsets in the ORACLE-MS

 

Study: Results from an Analysis of Lymphocyte Surface Markers

Leist T.402Session P1: Biomarkers and Experimental Studies for Multiple Sclerosis on

 

April 22, 2018

 

On Display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to

5:30 p.m. PDT

Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kgCook S.407Session P3: MS Therapeutics in Development on

 

April 24, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to

7:00 p.m. PDT

Effectiveness of Lymphocyte-based Re-treatment Criteria in

 

Minimizing the Incidence of Severe Sustained Lymphopenia During

Treatment with Cladribine Tablets 3.5mg/kg

Cook S.370Session P5: MS Therapies: MOA, Safety and Complications on

 

April 26, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to

7:00 p.m. PDT

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell SubsetsSoelberg-Sorensen P.364Session P5: MS Therapies: MOA, Safety and Complications on

 

April 26, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to 7:00 p.m. PDT

Selective and Discontinuous Reduction of B and T Lymphocytes and NK cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) After Administration of Cladribine TabletsStuve O.351Session P5: MS Therapies: MOA, Safety and Complications on

 

April 26, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to

7:00 p.m. PDT

Rebif® (interferon beta-1a) Presentations
TitleLead AuthorAbstract/Poster #Presentation Details
Relapse in Patients with Multiple Sclerosis Newly Initiating scIFNβ1a Compared with Oral Disease-Modifying Drugs: A Real-World AssessmentBowen J.353Session P1: Comparative Efficacy of Disease Modifying Therapies on April 22, 2018

 

 

On display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

A Panel Survey Analysis of Adherence in Patients with Multiple Sclerosis Treated with scIFNβ1a or Dimethyl FumaratePerrin Ross A.354Session P1: Comparative Efficacy of Disease Modifying Therapies on April 22, 2018

 

 

On display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

Disease Activity as Assessed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-Term Clinical Disease Activity (CDA)-Free Status and

 

Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a

(scIFNβ-1a)

Sormani M.P.005Session S24: MS

 

Outcome Measures and Biomarkers on April 24, 2018, 4:18 p.m.-4:30 p.m. PDT

Evolution of New Lesions and its Temporal Patterns in Patients with

 

Clinically Isolated Syndrome (CIS) Treated with Subcutaneous Interferon

beta-1a (scIFNß-1a)

Vrenken H.370Session P3: MS and CNS Inflammatory Disease: Neuroimaging on

 

April 24, 2018

 

On display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to 7:00 p.m. PDT

Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1aSabidó-Espin M.008Session S36: MS Therapeutics and Clinical Research on April 25, 2018

 

 

4:54 p.m. to 5:06 p.m. PDT

Cumulative Data from the European Interferon Beta Pregnancy

 

Registry

Hellwig K.357Session P4: Pregnancy and Multiple Sclerosis on April 25, 2018

 

 

On display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to 7:00 p.m. PDT

Impact of the Presence of Gadolinium-Enhancing (Gd+) Lesions at Baseline on No Evidence of Disease Activity (NEDA) Status in Patients Treated with Subcutaneous Interferon beta-1a (scIFNß-1a): A Post-hoc Analysis of REFLEXIONFreedman M.387Session P6:  MS Therapeutics: Extension Studies on April 27, 2018

 

 

On display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

Analysis of 6-month Confirmed Disability Progression in RRMS

 

Patients Treated with Subcutaneous Interferon beta-1a

Wong S.L.361Session P6: MS Therapeutics III on April 27, 2018

 

 

On display:11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

Full session details and data presentation listings for the 2018 AAN Annual Meeting can be found at the meeting website: https://www.aan.com/conferences-community/annual-meeting